Health · Healthcare & Policy · 58 mins ago
Australian advice says puberty blockers should remain an option for some young people
Australia's NHMRC says puberty blockers should remain a clinical option for some trans and gender-diverse young people.
These medicines pause aspects of physical development by suppressing sex hormones, and are used after puberty begins.
The advice is conditional because evidence about benefits and harms is uncertain, and it calls for decisions to be made by young people, carers and clinicians together.
The committee reviewed 15 non-randomised studies, mostly with follow-up of six months to two years, and said serious adverse events appeared rare.
It found the medicines may improve psychosocial functioning and may reduce suicidal behaviours, but found no eligible evidence on fertility or bone health.
The advice could affect Queensland and Northern Territory policies, where public-system access has been banned or restricted; it is not legally binding.
Public consultation is under way, with national guidelines due in 2028.
Australia’s National Health and Medical Research Council has issued interim advice that puberty blockers may be considered for some transgender and gender-diverse people under 18.
The advice makes treatment conditional on factors including having started puberty, clinical assessment and shared decision-making with the young person, their carers and clinicians.
The council says the evidence on benefits and harms is of low certainty, and recommends monitoring.
The advice is open for public consultation until 18 January.
Full guidelines covering other aspects of care, including gender-affirming hormones, are expected in 2028.
- Who
- Australia’s National Health and Medical Research Council issued the advice. It concerns transgender and gender-diverse people under 18.
- What
- The council says puberty blockers may be considered in certain circumstances, subject to conditions and individual assessment.
- When
- The interim advice was released on Monday, 16 November 2026.
- Where
- Australia.
- Why
- The federal government commissioned national guidance after Queensland and the Northern Territory restricted access to puberty blockers in public hospitals.
Advocates for access
Critics of puberty blockers
Purpose of treatment
Advocates for access
Advocates say pausing puberty can give young people time to decide whether to take further steps towards transitioning.
Critics of puberty blockers
Critics say the medication is experimental and potentially dangerous.
The federal government commissioned the NHMRC to develop national guidelines for care of transgender and gender-diverse young people.
The NHMRC released interim advice recommending conditional consideration of puberty blockers for some people under 18.
The public consultation on the interim advice is due to close.
Full guidelines, including advice on gender-affirming hormones, are expected.
- Age
- Under 18
- Eligibility
- Started puberty, assessed as suitable for treatment, and decision made jointly with the young person, carers and clinicians
- Evidence
- Low certainty, based largely on observational studies
- Consultation deadline
- 18 January
- Full guidelines
- Expected in 2028
4 sources
Butler challenges states to allow puberty blockers
Puberty blockers get interim green light for under 18s in Australia despite bans overseas
Australia’s national medical research body advises conditional use of puberty blockers for transgender children
Puberty blockers should remain an option for trans youth: national advice
What people are saying
A conditional recommendation is made in cases where shared decision-making is essential because different options may be appropriate for different individuals and they might make different choices, or where the overall certainty of available evidence is low. Both are the case here.
Not all young people will want or need the same intervention at the same time or age, and care that is in one young person's best interests may not suit another.
It is not a mental health disorder
Trans and gender-diverse young people experience unjust and avoidable health disparities arising from stigma, discrimination, and barriers to accessing health care